Adverum Biotechnologies Revenue vs. Gross Profit
| ADVM Stock | USD 5.69 0.20 3.40% |
Total Revenue | First Reported 2012-12-31 | Previous Quarter 0.0 | Current Value 1000 K | Quarterly Volatility 1.7 M |
For Adverum Biotechnologies profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Adverum Biotechnologies to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Adverum Biotechnologies utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Adverum Biotechnologies's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Adverum Biotechnologies over time as well as its relative position and ranking within its peers.
Adverum |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.95) | Revenue Per Share 0.059 | Quarterly Revenue Growth (0.70) | Return On Assets (0.30) | Return On Equity (0.76) |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Adverum Biotechnologies Gross Profit vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Adverum Biotechnologies's current stock value. Our valuation model uses many indicators to compare Adverum Biotechnologies value to that of its competitors to determine the firm's financial worth. Adverum Biotechnologies is rated below average in revenue category among its peers. It also is rated below average in gross profit category among its peers . At this time, Adverum Biotechnologies' Total Revenue is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Adverum Biotechnologies by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Adverum Revenue vs. Competition
Adverum Biotechnologies is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 170.71 Million. Adverum Biotechnologies holds roughly 3.6 Million in revenue claiming about 2.11% of equities under Health Care industry.
Adverum Gross Profit vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Adverum Biotechnologies |
| = | 3.6 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Adverum Biotechnologies |
| = | (81.68 M) |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Adverum Gross Profit Comparison
Adverum Biotechnologies is currently under evaluation in gross profit category among its peers.
Adverum Biotechnologies Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Adverum Biotechnologies, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Adverum Biotechnologies will eventually generate negative long term returns. The profitability progress is the general direction of Adverum Biotechnologies' change in net profit over the period of time. It can combine multiple indicators of Adverum Biotechnologies, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -473 K | -496.6 K | |
| Operating Income | -123.8 M | -130 M | |
| Income Before Tax | -118.2 M | -124.2 M | |
| Total Other Income Expense Net | 5.5 M | 5.8 M | |
| Net Loss | -117.2 M | -123 M | |
| Income Tax Expense | -1.1 M | -1 M | |
| Net Loss | -117.2 M | -123 M | |
| Non Operating Income Net Other | 177.1 K | 168.2 K | |
| Net Loss | -139.1 M | -146 M | |
| Change To Netincome | 18 M | 17.6 M | |
| Net Loss | (11.62) | (12.20) | |
| Income Quality | 0.78 | 0.51 | |
| Net Income Per E B T | 0.99 | 0.80 |
Adverum Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Adverum Biotechnologies. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Adverum Biotechnologies position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Adverum Biotechnologies' important profitability drivers and their relationship over time.
Use Adverum Biotechnologies in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adverum Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adverum Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Adverum Biotechnologies Pair Trading
Adverum Biotechnologies Pair Trading Analysis
The ability to find closely correlated positions to Adverum Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adverum Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adverum Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adverum Biotechnologies to buy it.
The correlation of Adverum Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adverum Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adverum Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adverum Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Adverum Biotechnologies position
In addition to having Adverum Biotechnologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sector ETFs Thematic Idea Now
Sector ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sector ETFs theme has 439 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sector ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
To fully project Adverum Biotechnologies' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Adverum Biotechnologies at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Adverum Biotechnologies' income statement, its balance sheet, and the statement of cash flows.